P2Y receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database


P2Y receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on P2Y Receptors [3, 5]) are activated by the endogenous ligands ATP, ADP, uridine triphosphate, uridine diphosphate and UDP-glucose. The relationship of many of the cloned receptors to endogenously expressed receptors is not yet established and so it might be appropriate to use wording such as 'uridine triphosphate-preferring (or ATP-, etc.) P2Y receptor' or 'P2Y1-like', etc., until further, as yet undefined, corroborative criteria can be applied [46, 109, 187, 375, 388].

Clinically used drugs acting on these receptors include the dinucleoside polyphosphate diquafosol, agonist of the P2Y2 receptor subtype, approved in Japan for the management of dry eye disease [236], and the P2Y12 receptor antagonists prasugrel, ticagrelor and cangrelor, all approved as antiplatelet drugs [52, 316].
How to Cite
Abbracchio, M.-P., Boeynaems, J.-M., Boyer, J. L., Burnstock, G., Ceruti, S., Fumagalli, M., Gachet, C., Hills, R., Humphries, R. G., Inoue, K., Jacobson, K. A., Kennedy, C., King, B. F., Lecca, D., Müller, C. E., Miras-Portugal, M. T., Ralevic, V. and Weisman, G. A. (2019) “P2Y receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database”, IUPHAR/BPS Guide to Pharmacology CITE, 2019(4). doi: 10.2218/gtopdb/F52/2019.4.